SCHEMBL6027770

SCHEMBL6027770

CC(C)Cn1c(=O)[nH]c(=O)c2ccccc21

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
TSHR P16473 2/20 0.53
HSD17B10 Q99714 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TP53 P04637 1/20 0.49
ALDH1A1 P00352 3/20 0.49
PARP1 P09874 9/20 0.48
KDM4E B2RXH2 2/20 0.47
HPGD P15428 1/20 0.47
DAO P14920 1/20 0.47
PARP2 Q9UGN5 3/20 0.46
B3GNT2 Q9NY97 1/20 0.46
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30704833 1.00 SMN1; SMN2 (0.53) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL17242599 0.88 PARP1 (0.49) ALDH1A1PARP1KDM4EDAOPARP2
SCHEMBL6300121 0.88 PARP1 (0.46) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL6027805 0.81 CYP1A2 (0.64) ALDH1A1PARP1KDM4EHPGDDAO
SCHEMBL6800624 0.80 DAO (0.43) PARP1DAOCYP1A2CYP2C19
SCHEMBL2267066 0.80 CYP1A2 (0.67) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL6295245 0.79 PARP1 (0.53) ALDH1A1PARP1DAOPARP2CYP1A2
SCHEMBL14160795 0.78 ALDH1A1 (0.63) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL2800361 0.77 BACE1 (0.63) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1
SCHEMBL29643235 0.77 BACE1 (0.63) SMN1; SMN2TSHRHSD17B10TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203003-A1 Notch Inhibitors and Uses Thereof STEMSYNERGY THERAPEUTICS, INC. 2023-06-29 US disclosed
US-8501786-B2 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 US disclosed
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2011-02-03 US disclosed
US-7018786-B2 Toning agents for use in thermographic recording materials AGFA GEVAERT (BE) 2006-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203003-A1 Notch Inhibitors and Uses Thereof NOTCH1, NOTCH2, NOTCH4 SMN1; SMN2 4659/4885TSHR 3942/4885HSD17B10 2619/4885
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 SMN1; SMN2 3396/4885TSHR 346/4885HSD17B10 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.